Platinum agents in the treatment of cancer

Expert Opinion on Investigational Drugs

Volumn 5, Issue 6, 1996, Pages 681-693

  Beale, Philip J ^a   Kelland, Lloyd R ^a   Judson, Ian R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

carboplatin; cisplatin; JM216; lobaplatin; nedaplatin; oxaliplatin

Indexed keywords

EID: 0009546081     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.5.6.681     Document Type: Review

References (74)

1. FORASTERIERE AA: An overview of platinum chemotherapy in head and neck cancer. Semin. Oncol. (1994) 21(Suppl. 12): 20-27.
2. KOSMIDES PA, SAMANTAS E, FOUNTZALIS G, PAVLIDIS N, APOSTOLOPOULOU F, SKARLOS D FOR THE HELLENIC COOPERATIVE ONCOLOGY GROUP FOR LUNG CANCER TRIALS: Cisplatin/etoposide versus carboplatln/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized Phase III study. Semin. Oncol. (1994) 21(Suppl. 6):6l-64.
3. KLASTERSKY J, SCULIER JP, LACROLX H, DABOUIS G, BUREAU G, LIBERT P, RICHEZ M, RAVE2 P, VANDER-MOTEN G, THIRIAUXJ, CORDIER R, FINET C, BERCHIER MC, SERGYSELS R, MOMMEN P, PAESMANS M: A randomized study comparing cisplatin or carboplatln with etoposide in patients with advanced non-small cell cancer: European Organization for Research and Treatment of Cancer protocol 07861. J. Clin. Oncol. (1990) 8(9):1556-1562. (Pubitemid 20301187)
4. BAJORIN DF, SAROSDY MF, PFISTER DG, MAZUMDAR M, MOTZER RJ, SCHER HI, GELLER NL, FAIR WR, HERR H, SOGANI P, SHEINFELD J, RUSSO P, VLAMIS V, CAREY R, VOGELZANG N, CRAWFORD ED, BOSL GJ: Randomized trial of etoposide and cisplatin versus etoposide and carboplatln in patients with good-risk germ cell tumours: a multi-institutional study. J. Clin. Oncol. (1993) ll(4):598-606. (Pubitemid 23105666)
5. HORWICH A, SLEIJFER D, FOSSA S, STENNING SP, COOK PA, SYLVESTER R, VERMEIJIEN K: A trial of carboplatln based chemotherapy in good prognosis metastatic testicular non seminoma [Abstract]. Proc. Am. Soc. Clin. Oncol. (1994) 13:231.
6. PATTE C, BARANZELLI MC, QUINTANA E, BOUFFET E, PORTAS M, PEREL Y: Carboplatln is less efficient than cisplatin in childhood non seminomatous germ cell tumour (NSGCT) treated in SFOP TGM 85 and TGM 90 protocols [Abstract]. Proc. Am. Soc. Clin. Oncol. (1995) 14:1396.
7. SCHIFF PB, FANT J, HOROWITZ SB: Promotion of micro tubular assembly invitro byTaxol. Nature(1979) 277:665-667.
8. MCGUIRE WP, HOSKINS WJ, BRADY MF, KUCERA PR, PARTRIDGE EE, LOOK KY, CLARKE-PEARSON DL, DAVID SON M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage m and stage IV ovarian cancer. New Engl. J. Med. (1996) 334(1): 1-6. (Pubitemid 26012496)
9. LANGER CJ, LEIGHTON JC, COMIS JC, O'DWYER PJ, MCALEER CA, BONJO CA, ENGSTROM PF, LITWTN S, OZOLS RF: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a Phase II toxicity, response and survival analysis. J. Clin. Oncol. (1995) 13(8):1860-1870.
10. O'REILLY SE, GELMON KA: Bi-weekly paclitaxel and cisplatin: a Phase I/H study in the first-line treatment of metastatic breast cancer. Semin. Oncol. (1995) 22(Suppl. 6):109-111.
11. AJANIJA, ILSON D, BHALLA K, FORASTIERE A, PAZDUR R, MARTIN L, DAUGHERTY K, KELSON DP: Taxol, cisplatin and 5-FU: a multi-Institutional Phase n study in patients with carcinoma of the oesophagus [Abstract]. Proc. Am. Soc. Clin. Oncol. (1995) 14:489.
12. HITT R, HORNEDO J, COLOMER R, MENDIOLA C. BRAN-DARIZ, SEVILLA E, ALVAREZ-VICENT J, CORTES-FUNEZ H: Phase I/n study of escalating doses of taxol and cisplatin with G-CSF as first line therapy for head and neck carcinomas. Preliminary results [Abstract]. Proc. Am. Soc. Clin. Oncol. (1995) 14:868.
13. BELLI L, LE CHEVAIER T, GOTTFRIED M, ADAMS D, RUFFIE P, LE CESNE A, TETE L, PELLAE-COSSET B: Phase I/n trial of paclitaxel and cisplatin in previously untreated advanced non-small cell lung cancer (NSCLC) [Abstract]. Proc Am. Soc. Clin. Oncol. (1995) 14:1058.
14. GIACCONE G, SPLINTER TAW, POSTMUS P, VAN MEER-BEECK J, DEBRUYNE C, SAHMOUD T: Tenlposide-cis-platln vs. paclitaxel-cisplatin in advanced non-small cell lung cancer (NSCLC). Results of a randomized Phase II study of EORTC-LCCG [Abstract]. Proc. Am. Soc. Clin. Oncol. (1995) 14:1082.
15. BERRY J, EZZAT A, EL WARITH A, RAJA MA, BAZAARBASHI S: Sequential taxol/cisplatin: pilot study in metastatic breast cancer [Abstract]. Proc. Am. Soc. Clin. Oncol. (1995) 14:243.
16. BROWNE MJ, KENNEDY T, CUMMINGS F, SKOV W, AKER-LEY W, DONEHOWER R, CLARK JW: Phase H study of sequential taxol and cisplatin for the treatment of metastatic breast cancer [Abstract]. Proc. Am. Soc. Clin. Oncol. (1995) 14:245.
17. OZOLS R: Carboplatin and paclitaxel in ovarian carcinoma. Semin. Oncol. (1995) 22(3 Suppl. 6):78-83.
18. CALVERT AH, BODDY A, BAILEY N, SIDDIQUI N, HUMPHREYS A, HUGHES A, HUGHES A, ROBSON L, GUMBRELL L, THOMAS H, CHAPMAN F, PROCTOR M, SIMMONS D, OAKEY A, LIND MJ, SINHA DV, NEWELL DR: Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interaction. Semin. Oncol. (1995) 22(3 Suppl. 6):91-98.
19. ZALCBERG J, BISHOP JF, MILLWARD MJ, ZIMET A, LAIRD J, BARTER C, SEWARD D, MCKEAGE MJ, FRIEDLANDER ML, TONER G, BERILLE J, BLANC C: Preliminary results of the first Phase n trial of docetaxel In combination with cisplatin in patients with metastatic or advanced non-small cell lung cancer (NSCLC) [Abstract]. Proc. Am. Soc. Clin. Oncol. (1995) 14:1062.
20. LE CHEVALIER T. BELLI L, MONNIER A, SUN XC, DOUIL-LARD JY, IBRAHIM N, SOULAS F, BERILLE J: Phase H study of docetaxel and cisplatin in advanced non-small cell lung cancer (NSCLC): an interim analysis [Abstract]. Proc. Am. Soc. Clin. Oncol. (1995) 14:1059.
21. VAN DER WALL E, BEIJNEN JH, RODENHUIS S: High dose chemotherapy regimens for solid tumours. Cancer Treatment Rev. (1995) 21:105-132.
22. JONES KB, SHPALL EJ, SHOGAN J, AFFRONTI ML, CONGLIO D, HART L, HALPERIN E, IGLEHART D, MOORE J, GOCK-ERMAN J, BAST RC, PETERS WP: The Duke AFM program. Cancer(1990) 66:431-36.
23. PETERS WP, SHPALL EJ, JONES RB, ROSS M: High-dose cyclophosphamide, cisplatin, and carmustine with bone marrow support as initial treatment for metastatic breast cancer: three-six year follow up. Proc. Am. Soc. Clin. Oncol. (1990) 9:10.
24. PETERS WP, SHPALL EJ, JONES RB et al: High dose combination chemotherapy alkylating agents-with bone marrow support as initial treatment for metastatic breast cancer. J. Clin. Oncol. (1988) 6(9):1368-1376. (Pubitemid 19089024)
25. PETERS WP, ROSS M, VREDENBURGH JJ, MEISENBERG B, MARKS LB, WINER E, KURTZBERG J, BAST RC, JONES R, SHPALL E, WU K, ROSNER G, GILBERT C, MATHIAS B, CONIGLIO D, PETROS W, HENDERSON C, NORTON L, WEISS RB, BUDMAN D, HURD D: High dose chemother apy and autologous bone marrow support as consoli dation after standard dose adjuvant therapy for high risk breast cancer. J. Clin. Oncol. (1993) 11(11):1132-1143. (Pubitemid 23163355)
26. STIFF P, BAYER R, CAMARDA M, TAN S, DOLAN J, POTKUL R, LOUTFI S, KINCH L, SOSMAN J, PEACE D, RAD N, MCKENZIE RS: A Phase H trial of high-dose mitoxan-trone, carboplatin and cyclophosphamide "with autolo gous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol. Oncol. (1995) 57:278-285.
27. HORWICH A: Salvage therapy of germ cell tumours. Br. J. Cancer (1995) 71(5):901-903.
28. SIEGERT W, BEYER J, STROHSCHEER I, BAURMANN H, OETTLE H, ZINGSEM J, ZIMMERMANN R, BOKEMEYER C, SCHMOLL HJ, HUHN D: High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a Phase I/n study. J. Clin. Oncol. (1994) 12(0:1223-1231. (Pubitemid 24173937)
29. LAMPE H, DEARNLEY D, PRICE A, MEHTA J, POWLES R, NICHOLS J, AND HORWICH A: High dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours. Eur. J. Cancer (1995) 31A(5):717-723.
30. BROUN ER, NICHOLS CR, KNEEBONE P, WILLIAMS SD, LOEHRER PJ, EINHORN LH, TRICOT GJK: Long-term outcome of patients with relapsed and refractory germ cell tumours treated with high-dose chemotherapy and autologous bone marrow rescue. Ann. Int. Med. (1992) 117(2):124-128.
31. BENEDETTI-PANICI P, GREGGI S, SCAMBIA G, SALERNO MG, BAIOCCHI G, LAURELLI G, MENICHELLA G, PIERELLI G, PIERELLI L, FODDAI ML, SERAFINIR, BIZZIB, MANCUSO S: Very high-dose chemotherapy-with autologous peripheral stem cell support in advanced ovarian cancer. Eur. J. Canceri (1995) 31A(12):1987-1992. (Pubitemid 26023088)
32. AYASH L, ELIAS A, WHEELER C, REICH E, SCHWARTZ G, MAZANET R, TEPLER I, WARREN D, LYNCH C, GONIN R, SCHNIPPER L, FREI E III, ANTMAN K: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J. Clin. Oncol. (1994) 12(1):37-44.
33. KELLAND LR: New platinum antitumor complexes. Crit. Rev. Oncol/Hematol. (1993) 15:191-219. (Pubitemid 24047767)
34. KELLAND LR, MURRER BA, ABEL G, GIANDOMENICO CM, MISTRY P, HARRAP KR: Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. (1992) 52:822-828.
35. KELLAND LR, ABEL G, MCKEAGE MJ, JONES M, GODDARD PM, VALENTI M, MURRER BA, HARRAP KR: Preclinical antitumor evaluation of bis-acetato-ammine-dichloro- cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res. (1993) 53:2581-2586. (Pubitemid 23168026)
36. MCKEAGE MJ, KELLAND LR, BOXALL FE, VALENTI MR, JONES M, GODDARD PM, GWYNNE J, HARRAP KR: Schedule dependency of orally administered bis-acetato-am-mine-dichloro cyclohexylamine-platinum (IV) (JM216) in vivo. Cancer Res. (1994) 54:4118-4122.
37. MCKEAGE MJ, MORGAN SE, BOXALL FE, MURRER BA, HARD GC, HARRAP KR: Preclinical toxicology and tissue distribution of novel oral antltumour platinum complexes: ammine/amine platinum(IV) dicarboxylates. Cancer Chemother. Pharmacol. (1994) 33:497-503. (Pubitemid 24082345)
38. MCKEAGE MJ, MORGAN SE, BOXALL FE, MURRER BA, HARD GC, HARRAP KR: Lack of nephrotoxicity of oral ammine/amine platinum(IV) dicarboxylate complexes in rodents. Br. J. Cancer (1993) 67:996-1000. (Pubitemid 23147491)
39. MCKEAGE MJ, BOXALL FE, JONES M, HARRAP KR: Lack of neurotoxicity of oral bisacetatoamine-dichloro cyclo-hexylamine platinum(IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res. (1994) 54:629-631.
40. MELLISH KJ, KELLAND LR, HARRAP KR: In vitro platinum drug chemosensitivity of intrinsic and acquired cis-platln-resistant human cervical carcinoma cell lines. Br. J. Cancer'(1993) 68:240-250. (Pubitemid 23229419)
41. MCKEAGE MJ, MISTRY P, WARD J, BOXALL FE, LOH S, O'NEILL C, ELLIS P, KELLAND LR, MORGAN SE, MURRER B, SANTABARBARA P, HARRAP KR, JUDSONIR: A Phase I and pharmacology study of an oral platinum complex (JM216): dose-dependent pharmacokinetics with single dose administration. Cancer Chemother. Pharmacol. (1995) 36:451-458.
42. MCKEAGE MJ, RAYNAUD FI, WARD J, BERRY C, ODELL D, MISTRY P, KELLAND LR, MURRER B, SANTABARBARA P, HARRAP KR, JUDSON IR: Phase I and pharmacokinetic study of an orally administered platinum (Pt) complex QM216) using a daily x 5 administration schedule [Abstract]. Proc. AmerSoc Clin Oncol. (1994) 13:136.
43. RAYNAUD FI, MCKEAGE MJ, WARD J, BERRY C, ODELL D, MURRER BA, SANTABARBARA P, JUDSON IR, HARRAP KR: Pharmacokinetic study of orally administered ammlne diacetato-dichloro (cyclohexylamine) platinum (IV) (JM216) in a 5-day dose schedule Phase I clinical trial. In: Novel Approaches in Anticancer Drug Design. Molecular Modelling-New Treatment Strategies. Zeller WJ, D'lncalci M, Newell DR (Eds.), Karger, Basel (1995) 49:100-108.
44. RAYNAUD FI, MISTRY P, DONAGHUE A, POON GK, KELLAND LR, BARNARD CFJ, MURRER BA, HARRAP KR: Biotransformation of the platinum drugJM2l6 following oral administration to cancer patients. Cancer Chemother. Pharmacol. (1996). In press.
45. BURCHENAL JH, KALAHER K, DEW K, LOKYS L: Rationale for development of platinum analogs. Cancer Treat. Rep. (1979) 63:1493-1498. (Pubitemid 10167744)
46. GODDARD PM, VALENTI MR, HARRAP KR: The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antltumour agents: a cautionary note. Ann. Oncol. (1991) 2:535-540.
47. SCHILDER RJ, LACRETA FP, PEREZ RP, JOHNSON SW, BRENNAN JM, ROGATKO A, NASH S, MCALEER C, HAMILTON TC, ROBY D, YOUNG RC, OZOLS RF, O'DWYER PJ: Phase I and pharmacokinetic study of ormaplatln (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res. (1994) 54:709-717. (Pubitemid 24068326)
48. O'ROURKE TJ, WEISS GR, NEW P, BURRIS HA, RODRIGUEZ G, ECKHARDT J, HARDY J, KUHN JG, FIELDS S, CLARK GM, VON HOFF DD: Phase I clinical trial of ormaplatln (tetraplatin, NSC 363812). Anticancer Drugs (1994) 5:520-526. (Pubitemid 24318679)
49. TUTSCH KD, AZOOMANIAN RZ, ALBERTID, FERERALIEND C, RALVINS HI, SPRIGGS DR: Phase I trial and pharmacokinetic study of ormaplatln [Abstract]. Proc. Am. Assoc. Cancer Res. (1992) 33:56.
50. EXTRA JM, ESPIE M, CALVO F, FERME C, MIGNOT L, MARTY M: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. (1990) 25:299-303 (Pubitemid 20014976)
51. PENDYALA L, CREAVE N: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. (1993) 53:5970-5976. (Pubitemid 24006168)
52. LEVI F, MISSET J-L, BRIENZA S, ADAM R, METZGER G, ITZAKHI M, CAUSSANEL J-P, KUNSTLINGER F, LECOUTU-REER S, DESCORPS-DECLERE A, JASMIN C, BISMUTH H, REINBERG A: A chronopharmacologic Phase n clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer (1992) 69:893-900.
53. LEVI FA, ZIDANI R, VANNETZEL J-M, PERPOINT B, FOCAN C, FAGGIUOLO R, CHOLLET P, GARUFI C, ITZHAKI M, DOGLIOTTI L, IACOBELLI S, ADAM R, KUNSTLINGER F, GASTIABURU J, BISMUTH H, JASMIN C, MISSET J-L: Chro-nomodulated versus fixed infusion-rate delivery of ambulatory chemotherapy-with oxaliplatin, fluorouraciL and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer Inst. (1994) 86:1608-1617. (Pubitemid 24336347)
54. LLORY JF, SOULIE P, CVITKOVIC E, MISSET JL: Feasibility of high-dose platinum delivery-with combined car-boplatin and oxallplatin. J. Natl. Cancer Inst. (1994) 86:1097-1098.
55. MACHOVER D, DIAZ-RUBIO E, DE GRAMONT A, SCHILF A, GASTIABURU J-J, BRIENZA S, ITZHAKI M, METZGER G, N'DAW D, VIGNOUD J, ABAD A, FRANCOIS E, GAMELIN E, MARTY M, SASTRE J, SEITZ J-F, YCHOU M: Two consecutive Phase n studies of oxallplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fhioropyrimidlnes. Ann. Oncol. (1996) 7:95-98. (Pubitemid 26051870)
56. HARSTRICK A, BOKEMEYER C, SCHARNOFKSE M, HAPKE G, REILE D, SCHMOLL H-J: Preclinical activity of a new platinum analogue, lobaplatin, in clsplatin-sensitive and-resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother. Pharmacol. (1993) 33:43-47. (Pubitemid 23336499)
57. GIETEMA JA, DE VRIES EGE, SLEIJFER DTH, WILLEMSE PHB, GUCHELAAR H-J, UGES DRA, AULENBACHER P, VOEGELI R, MULDER NH: A Phase I study of 1,2-dlam-mlno-methyl-cyclobutane-platlnum(II) lactate (D-19466; lobaplatin) administered dally for 5 days. Br. J. Cancer (1993) 67:396-401. (Pubitemid 23049570)
58. GIETEMA JA, GUCHELAAR H-J, DE VRIES E.G.E, AULENBACHER P, SLEIJFER DTH, MULDER NH: A Phase I study of lobaplatin (D-19466) administered by 72h continuous infusion. Anticancer Drugs (1993) 4:51-55. (Pubitemid 23063734)
59. GIETEMA JA, VELDHUIS G-J, GUCHELAAR H-J, WILLEMSE PHB, UGES DRA, CATS A, BOONSTRA H, VAN DER GRAAF WTA, SLEIJFER D TH, DE VRIES EGE, MULDER NH: Phase C and pharmacokinetic study of lobaplatin in patients-with relapsed ovarian cancer. Br. J. Cancer. (1995) 71:1302-1307.
60. KAVANAGH JJ, EDWARDS CL, FREEDMAN RS, FINNEGAN MB, BALAT O, TRESUKOSOL D, BURK K, LOECHNER S, HORD M, FRANKLIN J, KUDELKA AP: A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gyne col. Oncol. (1995) 58:106-109.
61. TRASK C, SILVERSTONE A, ASH CM, EARL H, IRWIN C, BARKER A, TOBIAS JS, SOUHAMI RL: A randomized trial of carboplatln versus iproplatin In untreated advanced ovarian cancer. J. Clin. Oncol. (1991) 9:1131-1137.
62. MAJIMA H: Clinical studies with cisplatin analogs, 254-S, DWA2114R and NK121. In: Platinum and other Metal Coordination Compounds in Cancer Chemotherapy. Howell SB (Ed.), Plenum Press, New York (1991):345-355.
63. OGAWA M: Clinical trials of 254-S, NK121 and TRK-710 [Abstract]. Proc. 7th International Symposium on Platinum and other Metal Coordination Compounds in Cancer Chemotherapy (1995):129.
64. FUKUDA M, SHINKAI T, EGUCHI K, SASAKI Y, TAMURA T, OHE Y, KOJIMA A, OSHITA F, HARA K, SAIJO N: Phase H study of (glycolate-0,00 dlammlneplatlnum(n), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother. Pharmacol. (1990) 26:393-396. (Pubitemid 20333740)
65. AKAZA H, TOGASHI M, NISHIO Y, MIKI T, KOTAKE T, MATSUMURA Y, YOSHIDA O, ASO Y: Phase H study of cs-diammine(glycolato)platlnum, 254-S, In patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract, Cancer Chemother. Pharmacol., 1992, 31, 187-192
66. O'DWYER PJ, HUDES GR, WALCZAK J, SCHILDER R, LACRETA F, ROGERS B, COHEN I, KOWAL C, WHITFIELD L, BOYD RA: Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-dally dose schedule. Cancer Res. (1992) 52:6746-6753. (Pubitemid 23006273)
67. THERIAULT RL, COHEN IA, ESPARZA L, KOWAL C, RABER MN: Phase I clinical evaluation of [SP-4-3(R)]-[l,l-cy-clobutanedicarboxylato(2-)] (2-methyl-l,4-bu-lanedlamlne-A,Af') platinum in patients with metastatic solid tumors. Cancer Chemother. Pharmacol. (1993) 31:333-337. (Pubitemid 23029161)
68. IMANISHI H, MUTOH M, SAITO Y, TAMAOKA M, OHTA S, OKAMOTO Z, FURUKAW A: Antitumor activity, toxicity and pharmacokinetics of TRK-710, a new platinum complex active against cisplatin-resistant tumors [Abstract]. Proc. 7th International Symposium on Platinum and other Metal Coordination Compounds in Cancer Chemotherapy (1995):104.
69. DREES M, DENGLER WM, HENDRIKS HR, KELLAND LR, FIEBIG HH: Cycloplatam: a novel platinum compound exhibiting a different spectrum of antitumour activity to cisplatin. Eur. J. Cancer(1995) 31A: 356-361.
70. KELLAND LR, JONES M, ABEL G, VALENTI M, GWYNNE JJ, HARRAP KR: Human ovarian carcinoma cell lines and companion xenografts: a disease oriented approach to new platinum anticancer drug development. Cancer Chemother. Pharmacol. (1992) 30:43-50.
71. KELLAND LR, MISTRY P, ABEL G, LOH SY, O'NEILL, HARRAP KR: Mechanism-related circumvention of acquired rfs-diamminedichloroplatlnum(n) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. (1992) 52:3857-3864.
72. KELLAND LR, BARNARD CFJ, MELLISH KJ, JONES M, GOD-DARD PM, VALENTI M, BRYANT A, MURRER BA, HARRAP KR: A novel rns-platinum coordination complex possessing in vitro and in vivo antitumour activity. Cancer Res. 1994; 54: 5618-5622. (Pubitemid 24346257)
73. MELLISH KJ, BARNARD CFJ, MURRER BA, KELLAND LR: DNA binding properties of novel cis-and trans-platinum-based anticancer agents in two human ovarian carcinoma cell lines. Int. J. Cancer (1995) 62:717-723.
74. KELLAND LR, HOLFORD J, HARTLEY JA, MURRER BA, HARRAP KR: Ammine/amine platinum (IV) Dicarboxylates: a novel stericahy hindered platl-num(H) complex showing non cross-resistance properties to cisplatin. Proc. Am. Assoc. Cancer Res. (1996). In press.